Studii clinice pentru BPOC în Alabama
21 studii pentru BPOC caută participanți în Alabama.
Orașe în Alabama
Text oficial al studiului (în engleză)
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- University of Alabama at Birmingham- Site Number : 8400003, Birmingham
- Pulmonary Associates - Mobile- Site Number : 8400151, Mobile
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 1 oct. 2026 · NCT07190222A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- University of Alabama at Birmingham, Birmingham
În curs de recrutareFaza 2
Vârste de la 40 la 75 · Toate sexele · Actualizat 25 sept. 2026 · NCT07759245A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- University of Alabama at Birmingham - School of Medicine- Site Number : 8400003, Birmingham
În curs de recrutareFaza 4
Vârste de la 40 la 85 · Toate sexele · Actualizat 22 sept. 2026 · NCT07053423A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Birmingham
În curs de recrutareFaza 2
Vârste de 40 ani și peste · Toate sexele · Actualizat 9 sept. 2026 · NCT07082738Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- University of Alabama, Birmingham
În curs de recrutareFaza 2
Vârste de 40 ani și peste · Toate sexele · Actualizat 4 sept. 2026 · NCT07059091A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Cullman
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 3 sept. 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Foley
- Research Site, Mobile
- Research Site, Sheffield
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 3 sept. 2026 · NCT06883305A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
- University of Alabama at Birmingham, Birmingham
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 sept. 2026 · NCT06603246A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- University of Alabama at Birmingham Lung Health Center, Birmingham
- SEC Clinical Research, Dothan
- Pulmonary Associates of Mobile, P.C., Mobile
În curs de recrutareFaza 2/3
Vârste de la 35 la 80 · Toate sexele · Actualizat 31 aug. 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Cullman
- Research Site, Mobile
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 26 aug. 2026 · NCT06283966A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 106, Birmingham
În curs de recrutareFaza 3
Vârste de la 18 la 80 · Toate sexele · Actualizat 11 aug. 2026 · NCT07555483Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities
- Cooper Green Mercy Hospital, Birmingham
În curs de recrutareStudiu observațional
Vârste de la 50 la 99 · Toate sexele · Actualizat 6 aug. 2026 · NCT07748858Multi-Center Clean Air Randomized Controlled Trial in COPD
- University of Alabama, Lung Health Center, Birmingham
În curs de recrutareFaza 3
Vârste de 40 ani și peste · Toate sexele · Actualizat 31 iul. 2026 · NCT06376994Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
- The University of Alabama at Birmingham, Birmingham
În curs de recrutare
Vârste de 22 ani și peste · Toate sexele · Actualizat 23 iun. 2026 · NCT07222410SPIROMICS Study of Early COPD Progression (SOURCE)
- University of Alabama at Birmingham, Birmingham
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
Vârste de la 30 la 55 · Toate sexele · Actualizat 3 iun. 2026 · NCT05033990Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
- University of Alabama-Birmingham Hospital - UAB Lung Health Center, Birmingham
În curs de recrutare
Vârste de la 40 la 80 · Toate sexele · Actualizat 28 apr. 2026 · NCT07051707Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
- University of Alabama at Birmingham, Birmingham
În curs de recrutare
Vârste de la 40 la 84 · Toate sexele · Actualizat 24 apr. 2026 · NCT06891755Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Sheffield
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 9 apr. 2026 · NCT06961214PiMZ Longitudinal Cohort (PiMZ Logic)
- University of Alabama at Birmingham, Birmingham
În curs de recrutareStudiu observațional
Vârste de 18 ani și peste · Toate sexele · Actualizat 16 ian. 2026 · NCT06505603Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
- University of Alabama at Birmingham, Birmingham
În curs de recrutareFaza 4
Vârste de 19 ani și peste · Toate sexele · Actualizat 10 nov. 2025 · NCT07135427myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- UAB School of Medicine/Lung Health Center, Birmingham
În curs de recrutare
Vârste de 30 ani și peste · Toate sexele · Actualizat 6 feb. 2025 · NCT05204888Sursă: ClinicalTrials.gov, date preluate la 2 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.